Agrawal Rashi, Aggarwal Nelesh, Swasti Swasti, Mittal Kailash, Sharma Arnav
Radiation Oncology, Max Super Speciality Hospital, Ghaziabad, IND.
Gynecologic Oncology, Max Super Speciality Hospital, Ghaziabad, IND.
Cureus. 2024 Oct 27;16(10):e72462. doi: 10.7759/cureus.72462. eCollection 2024 Oct.
The preferred treatment for medically inoperable early-stage endometrial cancer (EC) is definitive radiation therapy (RT), either in the form of brachytherapy (BT) alone or in combination with external beam radiotherapy (EBRT). This case report details a modified brachytherapy approach for a 59-year-old female patient who was known to have multiple comorbidities, poor performance status, and progressive slowness in activities of daily living. She presented with a complaint of post-menopausal bleeding per vaginum, for which she underwent investigations and was diagnosed with a case of endometrial adenocarcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IA and grade I. After the tumor board discussion, the patient was deemed medically inoperable and planned for radical radiotherapy. She received EBRT via the image-guided intensity-modulated radiotherapy technique, a dose of 50.4 Gy in 28 fractions to the uterus, cervix, and upper 2 cm of the vagina, followed by weekly intracavitary brachytherapy (ICBT), a dose of 4.5 Gy in the first fraction via the Rotte-Y applicator and 5.2 Gy in the second and third fractions each via the modified Rotte-Y applicator. The modified applicator demonstrated better coverage of the target with a lesser dose to the organs at risk (OARs) and underscores its potential use in the future for such cases.
对于医学上无法手术的早期子宫内膜癌(EC),首选的治疗方法是根治性放射治疗(RT),可以是单纯近距离放射治疗(BT),也可以是与外照射放疗(EBRT)联合使用。本病例报告详细介绍了一种改良的近距离放射治疗方法,用于一名59岁的女性患者,该患者患有多种合并症,身体状况较差,日常生活活动逐渐迟缓。她因绝经后阴道出血前来就诊,为此接受了检查,并被诊断为子宫内膜腺癌,国际妇产科联盟(FIGO)IA期,I级。经过多学科会诊讨论,该患者被认为医学上无法手术,计划进行根治性放疗。她通过图像引导调强放疗技术接受了EBRT,给予子宫、宫颈和阴道上2 cm 50.4 Gy的剂量,分28次照射,随后每周进行腔内近距离放射治疗(ICBT),第一次通过Rotte-Y施源器给予4.5 Gy的剂量,第二次和第三次分别通过改良的Rotte-Y施源器给予5.2 Gy的剂量。改良施源器显示出对靶区的覆盖更好,对危及器官(OARs)的剂量更小,并强调了其在未来此类病例中的潜在应用价值。